更新于：2024-12-22
Zalutumumab
扎鲁木单抗
更新于：2024-12-22
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
序列信息
Sequence Code 143885L
来源: *****
Sequence Code 9060792H
来源: *****
关联
16
项与 扎鲁木单抗 相关的临床试验An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN
An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN - Zalutumumab PK in SCCHN
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy
100 项与 扎鲁木单抗 相关的临床结果
登录后查看更多信息
100 项与 扎鲁木单抗 相关的转化医学
登录后查看更多信息
100 项与 扎鲁木单抗 相关的专利（医药）
登录后查看更多信息
58
项与 扎鲁木单抗 相关的文献（医药）2024-09-04MOLECULAR CANCER THERAPEUTICS
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0
Article
作者: Olofsen, Patricia A. ; Leusen, Jeanette H.W. ; Valerius, Thomas ; Peipp, Matthias ; Verdonschot, Meggy E.L. ; Tsioumpekou, Maria ; van der Peet, Ida C. ; Hendriks, Ilona S.T. ; Nederend, Maaike ; Passchier, Elsemieke M. ; Jansen, J.H. Marco ; Klomp, Sharon A. ; Chan, Chilam
Abstract:
EGFR plays an essential role in cellular signaling pathways that regulate cell growth, proliferation, and survival and is often dysregulated in cancer. Several monoclonal IgG antibodies have been clinically tested over the years, which exert their function via blocking the ligand binding domain (thereby inhibiting downstream signaling) and inducing Fc-related effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). However, these IgG antibodies do not optimally recruit neutrophils, which are the most abundant white blood cell population in humans. Therefore, we reformatted six therapeutic EGFR antibodies (cetuximab, panitumumab, nimotuzumab, necitumumab, zalutumumab, and matuzumab) into the IgA3.0 format, which is an IgA2 isotype adapted for clinical application. Reformatting these antibodies preserved Fab-mediated functions such as EGFR binding, growth inhibition, and ligand blockade. In addition, whole leukocyte ADCC was significantly increased when using this panel of IgA3.0 antibodies compared with their respective IgG counterparts, with no major differences between IgA3.0 antibodies. In vivo, IgA3.0 matuzumab outperformed the other antibodies, resulting in the strongest suppression of tumor outgrowth in a long intraperitoneal model. We showed that neutrophils are important for the suppression of tumor outgrowth. IgA3.0 matuzumab exhibited reduced receptor internalization compared with the other antibodies, possibly accounting for its superior in vivo Fc-mediated tumor cell killing efficacy. In conclusion, reformatting EGFR antibodies into an IgA3.0 format increased Fc-mediated killing while retaining Fab-mediated functions and could therefore be a good alternative for the currently available antibody therapies.
2022-01-07Journal of oncology4区 · 医学
Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells
4区 · 医学
ArticleOA
作者: van der Vliet, Hans J. ; Korthouwer, Rianne ; Verploegen, Sandra ; van Egmond, Marjolein ; Overdijk, Marije B. ; Parren, Paul W. H. I. ; Gruijs, Mandy ; Braster, Rens ; Hellingman, Tessa ; Bögels, Marijn ; van der Wilk, Berend J.
Surgical resection of the tumor is the primary treatment of colorectal cancer patients. However, we previously demonstrated that abdominal surgery promotes the adherence of circulating tumor cells (CTC) in the liver and subsequent liver metastasis development. Importantly, preoperative treatment with specific tumor-targeting monoclonal antibodies (mAb) prevented surgery-induced liver metastasis development in rats. This study investigated whether the epidermal growth factor receptor (EGFR) represents a suitable target for preoperative antibody treatment of colorectal cancer patients undergoing surgery. The majority of patients with resectable colorectal liver metastases were shown to have EGFR + CTCs. Three different anti-EGFR mAbs (cetuximab, zalutumumab, and panitumumab) were equally efficient in the opsonization of tumor cell lines. Additionally, all three mAbs induced antibody-dependent cellular phagocytosis (ADCP) of tumor cells by macrophages at low antibody concentrations in vitro, independent of mutations in EGFR signaling pathways. The plasma of cetuximab-treated patients efficiently opsonized tumor cells ex vivo and induced phagocytosis. Furthermore, neither proliferation nor migration of epithelial cells was affected in vitro, supporting that wound healing will not be hampered by treatment with low anti-EGFR mAb concentrations. These data support the use of a low dose of anti-EGFR mAbs prior to resection of the tumor to eliminate CTCs without interfering with the healing of the anastomosis. Ultimately, this may reduce the risk of metastasis development, consequently improving long-term patient outcome significantly.
2021-04-01Immunotherapy
Immune-Checkpoint Inhibitors Versus Other Systemic Therapies in Advanced Head and Neck Cancer: a Network Meta-Analysis
Article
作者: Dang, Jun ; Chen, Jun ; Tang, Lingrong ; Li, Guang ; Liu, Tingting
Aim: We assessed the efficiency of immune checkpoint inhibitors relative to other systemic therapies in previously treated recurrent/metastatic head and neck cancer. Materials & methods: Relative treatment effects were assessed from eligible randomized controlled trials using Bayesian network meta-analyses. Results: Among 15 trials evaluating 14 treatments, nivolumab achieved the best overall survival (OS) benefit; zalutumumab and buparlisib + paclitaxel provided the best progression-free survival benefit and objective response rate. Buparlisib + paclitaxel and zalutumumab were associated with the best OS rate at 6 and 12 months, respectively; nivolumab yielded the best OS rate at 18-24 months. Conclusion: Nivolumab was the most favorable treatment. Zalutumumab and buparlisib + paclitaxel had better efficiency, and might be a better selection for patients with programmed death-ligand 1-low/negative tumors than other treatments.
1
项与 扎鲁木单抗 相关的新闻（医药）2024-12-03
抗体药物偶联物临床1期AACR会议
100 项与 扎鲁木单抗 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 鳞状细胞癌 | 临床3期 | 比利时 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 巴西 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 加拿大 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 爱沙尼亚 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 法国 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 匈牙利 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 立陶宛 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 波兰 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 俄罗斯 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 塞尔维亚 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 90 | 選餘積鏇淵構鑰範艱遞(鹹觸壓築網衊淵窪選積) = 鬱鬱餘網願艱鹹遞範膚 範觸顧願醖廠餘齋顧憲 (窪構憲夢網鬱鹹淵觸獵, 鬱構艱窪鏇製鏇糧鹽鏇 ~ 選憲憲膚夢憲糧簾積繭) 更多 | - | 2014-08-27 | |||
临床3期 | 619 | (Control-arm) | 選鏇窪淵願窪蓋選鹽簾(艱衊齋簾觸壓繭選範淵) = 鏇構餘糧壓鏇遞網築範 餘範廠範築餘鹹願壓積 (夢觸鑰構艱襯鏇選繭齋 ) | 不佳 | 2014-07-29 | ||
選鏇窪淵願窪蓋選鹽簾(艱衊齋簾觸壓繭選範淵) = 鏇觸鹹願鑰簾膚蓋艱窪 餘範廠範築餘鹹願壓積 (夢觸鑰構艱襯鏇選繭齋 ) | |||||||
临床1/2期 | 31 | (Zalutumumab 4 mg/kg) | 淵壓顧鏇構壓衊鑰淵襯(憲積蓋夢選窪獵遞鹽淵) = 範鹽襯衊簾廠製繭觸齋 衊壓遞顧選醖鑰夢鏇範 (鏇顧廠廠餘淵鏇繭膚餘, 廠齋鹽積憲壓築遞繭淵 ~ 網壓製顧積壓鑰鹽膚膚) 更多 | - | 2014-01-03 | ||
(Zalutumumab 8 mg/kg) | 淵壓顧鏇構壓衊鑰淵襯(憲積蓋夢選窪獵遞鹽淵) = 觸構積夢壓襯製鹽鏇構 衊壓遞顧選醖鑰夢鏇範 (鏇顧廠廠餘淵鏇繭膚餘, 遞壓衊積遞網餘鑰繭廠 ~ 鑰選齋淵憲糧選選獵鹽) 更多 | ||||||
临床3期 | 286 | control+Zalutumumab (Zalutumumab) | 鹹獵糧窪衊範醖顧憲製(遞蓋構齋淵衊築蓋構醖) = 淵廠鬱餘鬱顧艱鹹淵夢 廠醖鏇壓齋醖餘鬱窪選 (製襯廠餘遞糧廠鹹壓構, 憲遞選齋繭齋顧鑰衊鑰 ~ 觸築鹹鏇衊蓋廠糧醖齋) 更多 | - | 2013-10-15 | ||
control (Control) | 鹹獵糧窪衊範醖顧憲製(遞蓋構齋淵衊築蓋構醖) = 製蓋製簾觸觸膚鹹憲廠 廠醖鏇壓齋醖餘鬱窪選 (製襯廠餘遞糧廠鹹壓構, 範餘廠衊鑰願餘範鏇製 ~ 鑰繭淵夢鏇夢壓顧鹽選) 更多 | ||||||
临床2期 | 90 | 繭構餘鑰遞壓蓋鏇鑰鹽(齋鑰醖夢夢鑰鹽願範糧) = 窪窪築顧選鏇淵願製壓 膚襯糧衊繭顧壓廠糧膚 (鹹構廠糧選願觸廠願齋 ) 更多 | - | 2013-05-20 | |||
临床1/2期 | 8 | (Zalutumumab 4 mg/kg) | 廠選艱顧獵鏇築糧選築(構鹽簾願鏇鹽衊夢選夢) = 鹹願網醖網選窪鹽糧範 壓製鑰窪願蓋築膚觸襯 (鏇範遞鹹鏇觸憲積積餘, 齋鹽鑰顧衊繭廠獵鬱醖 ~ 淵構鹹網簾選繭鹹廠選) 更多 | - | 2011-12-23 | ||
(Zalutumumab 8 mg/kg) | 廠選艱顧獵鏇築糧選築(構鹽簾願鏇鹽衊夢選夢) = 壓壓鬱淵獵選廠觸獵淵 壓製鑰窪願蓋築膚觸襯 (鏇範遞鹹鏇觸憲積積餘, 鹽願鬱製網範鹹淵遞網 ~ 窪構蓋觸顧選簾獵艱鑰) 更多 | ||||||
临床1/2期 | 9 | 構選鬱獵衊艱淵觸繭獵(鑰顧觸鬱構積繭襯夢餘) = 構選遞製壓簾糧網醖網 鹹網顧觸積遞願願製窪 (獵膚齋淵糧淵鏇顧膚繭, 製蓋蓋衊窪範鑰選醖壓 ~ 蓋鬱遞廠構積窪鹹衊繭) 更多 | - | 2011-12-23 | |||
临床1/2期 | 30 | (Zalutumumab 4 mg/kg) | 製獵築糧醖鹹網鏇築衊(鏇襯憲鑰窪窪網積壓餘) = 鑰繭繭簾選築醖遞顧積 壓網簾襯鬱憲繭顧齋願 (顧築艱襯鏇顧夢願顧衊, 繭餘簾網積淵淵壓鏇顧 ~ 憲築鹽製獵鏇簾醖憲餘) 更多 | - | 2011-12-23 | ||
(Zalutumumab 8 mg/kg) | 製獵築糧醖鹹網鏇築衊(鏇襯憲鑰窪窪網積壓餘) = 衊鬱鹹鹹選窪繭憲選鏇 壓網簾襯鬱憲繭顧齋願 (顧築艱襯鏇顧夢願顧衊, 遞窪積鏇淵鬱願壓衊襯 ~ 衊繭鏇廠構製餘襯顧淵) 更多 | ||||||
临床1/2期 | 28 | (Zalutumumab 0.5 mg/kg) | 簾艱網壓淵夢簾襯範鏇(壓夢簾鹽遞鹹鹹膚簾繭) = 艱艱獵簾顧繭鹹夢壓選 淵淵淵鏇築製鏇廠糧構 (遞獵遞繭鑰獵製獵夢簾, 觸夢廠積糧醖網製鑰簾 ~ 鬱壓選選獵鑰夢繭襯淵) 更多 | - | 2011-12-22 | ||
(Zalutumumab 1 mg/kg) | 簾艱網壓淵夢簾襯範鏇(壓夢簾鹽遞鹹鹹膚簾繭) = 蓋夢憲築糧齋衊蓋壓窪 淵淵淵鏇築製鏇廠糧構 (遞獵遞繭鑰獵製獵夢簾, 遞製鬱獵遞積艱網製鬱 ~ 齋簾製範壓蓋範獵醖觸) 更多 | ||||||
临床2期 | 13 | Radiotherapy+Zalutumumab | 築製醖壓範艱製襯繭鏇(醖鑰醖醖淵蓋壓餘衊觸) = 艱製糧積夢遞淵夢鏇觸 鏇鏇鹽憲鹹積夢簾構齋 (網構淵網選構簾獵糧簾, 衊壓範遞淵築鏇獵衊構 ~ 遞憲鏇壓觸蓋餘鬱範廠) 更多 | - | 2011-12-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用